immunotherapy
The findings of a recent study suggest that targeting the interactions between MAdCAM-1 and specific receptors on the surface of immune cells may help to improve immunotherapy outcomes.
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
New studies provide evidence that there may be fungi within tumors and could also help to diagnose certain types of cancer or predicting their course.
A gut microbial metabolite called trimethylamine N-oxide, or TMAO, could improve immunotherapy success in pancreatic cancer.
Researchers have found that a specific microbial metabolite may boost the efficacy of anticancer therapy in people with TNBC. The findings could inform the development of improved treatments for TNBC.
Akkermansia can be used as a biomarker to identify who is likely to respond to treatment with immune checkpoint inhibitors. A new study published in Nature Medicine claims
A study published in Nature Medicine claims that the manipulation of the gut microbiota could be a new strategy to treat toxicity to combined immunotherapy.
